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Abstracts / Osteoarthritis and Cartilage 20 (2012) S54–S296S80Conclusions: The current study provides a comprehensive proﬁle of
cytokines, chemokines and growth factors present in the OA and the
healthy joint environment. Increased soluble mediators, such as IL-6, IP-10,
MDC and RANTES, indicate the involvement of a catabolic process in OA.
This biomarker proﬁle might be useful to distinguish OA patients from
healthy donors, however needs to be validated in future experiments.
148
A NEW SANDWICH BIOMARKER ASSAY FOR CARTILAGE TYPE II
COLLAGEN CAN DISCRIMINATE BETWEEN NO OSTEOARTHRITIS (OA),
PRE-RADIOGRAPHIC AND RADIOGRAPHIC KNEE OA IN HUMAN URINE.
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Purpose: Molecular biomarkers, especially those that detect cleavage of
cartilage type II collagen, offer the potential to detect early pre-radio-
graphic osteoarthritis (PROA) and radiographic OA (ROA). Increased
type II collagen cleavage by collagenases is a well-established feature in
OA knee articular cartilage. Yet existing assays have exhibited limited
ability to discriminate between these patient populations and those
without OA. By focusing on a 45 mer collagenase-generated peptide of
type II collagen found in increased amounts in urine of OA patients
(Nemirovskiy et al, 2007), a new assay has been developed that can
discriminate knee PROA and knee ROA from subjects with no detectable
OA (NoOA) on magnetic resonance imaging (MRI). Initial encouraging
results are presented here.
Methods: The newly developed sandwich assay for urine (IB-C2C-
HUSATM) detects the type II collagen speciﬁc C-terminus of the 3/4 piece
generated by collagenase and an intrachain epitope within 45 residues of
this cleavage site. This was compared to an existing competitive inhibition
assay (C2C ELISA) that also detects this cleavage site neoepitope in type II
collagen alpha-chains and any other alpha-chain fragments containing this
neoepitope. Assay results were expressed as pg per mmol creatinine. Urine
samples from the population-based Model for the Diagnosis of Early Knee
Osteoarthritis (MoDEKO) cohort were analyzed. The unique MoDEKO
cohort consists of subjects with knee pain, age 40 to 79, classiﬁed based on
knee MRI and x-ray (34 NoOA; 120 PROA and 98 ROA_sample-weighted
counts). Data were analyzed for differences between OA subgroups using
descriptive statistics. Multinomial logistic regression analysis was per-
formed to evaluate the associations between biomarkers and radio-
graphically/MRI deﬁned OA subgroups vs. NoOA, reported as odds ratios
(ORs) and 95% conﬁdence intervals (CI) after log-transformation and
adjustment for age, gender and BMI. All analyses were sample-weighted.
Results: Results for the C2C ELISA inhibition assay revealed no ability to
discriminate between the different groups in urine (Fig.1). In contrast, the
IB-C2C-HUSATM sandwich assay revealed the presence of progressively
higher concentrations of the cleavage neoepitope in PROA and ROA groups
compared to the NoOA group (Fig.1). Multinomial logistic regression
results revealed that the new urine assay could signiﬁcantly predict the
three groups (overall p <0.001): OR 2.90 (95% CI 1.64, 5.13) for ROA vs.
NoOA, OR 1.55 (95% CI 0.95, 2.50) for PROA vs. NoOA and OR 1.88 (95% CI
1.27, 2.77) for ROA vs. PROA. Interestingly, this discrimination was often
stronger when urine data were not corrected for creatinine: OR 3.97 (2.03,
7.78) for ROA vs. NoOA ; OR 2.30 (1.22, 4.32) for PROA vs. NoOA and OR 1.73
(1.23, 2.43) for ROA vs. PROA.
Conclusions: Our results demonstrate the ability of this new urine-speciﬁc
sandwich assay to discriminate between NoOA, PROA and ROA in amanner
not previously possible with the original C2C inhibition assay. It also
provides further evidence to suggest that the 45mer alpha-chain fragment
of type II collagen, that contains the collagenase cleavage site, is generated
in increased amounts in knee OA and can be selectively detected in urine.
This new biomarker assay may be of value in studying disease onset,
progression and treatment in OA.Ă
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MEASUREMENTS OF URINARY COLL2-1NO2 IS PREDICTIF OF JOINT
SPACE NARROWING IN KNEE OSTEOARTHRITIS
Y. Henrotin 1, V. Kraus 2, K.D. Brandt 3, S.A. Mazzuca 3, J. Huebner 2,
B. Boulanger 4, M. Deberg 5. 1Bone and Cartilage Res. Unit, Liège, Belgium;
2Duke Univ. Med. Ctr., Durham, NC; 3Univ. Sch. of Med., Indianapolis, IN;
4Arlenda SA, Liège, Belgium; 5Artialis SA, Liège, BelgiumPurpose: To evaluate the predictive value of Coll2-1NO2, a biochemical
marker of inﬂammation-related cartilage degradation, for radiographic
knee osteoarthritis (OA) progression. Coll2-1NO2 [HRGY(NO2)PGLDG], is
the nitrated from of Coll2-1 (HRGYPGLDG), a denaturation epitope of the
type II collagen molecule.
Methods: Two OA populations were studied: population 1 was composed
by 135 obese men andwomen aged 45 to 64 years with mild andmoderate
knee OA (presence of osteophytes and a minimum joint space width  2
mm in themedial compartment); population 2 included 182 obesewomen
with unilateral radiographic knee OA (K&L II or III) aged 45 to 64 years from
the placebo arm of the doxycycline study (Brandt et al., 2004). For both
populations, quantitative estimates of changes in joint space width (JSW)
in the medial tibiofemoral compartment were obtained from ﬂuoroscop-
ically assisted semi-ﬂexed AP radiographs performed at baseline,16 and 30
months. The creatinine-adjusted urinary Coll2-1NO2 (uColl2-1NO2)
concentrationwas measured on samples obtained at baseline, after 16 and
30 months for the patients from population 1 and at baseline and after 6,
12, 18, 24 and 30 months for the patients from population 2. Patients
showing a decrease of JSW  0.5 mm over 30 months follow-up were
designated radiographic progressors. The comparison of progressor and
nonprogressor patients at inclusion was performed by an unpaired t-test.
The results were expressed as medians (minimum and maximum). The
ability of biomarker to predict radiographic progression of knee osteoar-
thritis was evaluated by logistic regression analysis. The covariates in the
model are uColl2-1NO2 at baseline and the change over 16 months of
uColl2-1NO2.
Abstracts / Osteoarthritis and Cartilage 20 (2012) S54–S296 S81Results: Population 1: The 135 subjects were, on average, 60.73 years old
and had a BMI of 32.77 kg/m2. The median minimum JSW at inclusion was
3.58 mm (min: 0.30 mm- max: 5.99 mm). After 16 and 30 months follow-
up, the minimum JSW were 3.38 mm (min: 0 mm- max: 5.80 mm) and
2.96 mm (min: 0 mm- max: 5.99 mm), respectively. At 30 months follow-
up, linear regression analysis showed that 85% of the subjects had expe-
rienced a JSW decrease. After 30 months, 61 patients (45.2%) were radio-
graphic progressors. By logistic regression, we observed that patients with
an increase of uColl2-1NO2 over 16 months (> 0.052 nmol/mmol Cr) had
a high probability (82%) of being radiographic progressors (p<0.001). By
contrast, patients with a decrease of uColl2-1NO2 over 16 months (a
decrease more than 0.114 nmol/mmol Cr) had a high probability (80%) of
being nonprogressors (p<0.01).
Population 2: The 182 women were, on average, 53.54 years old and had
a BMI of 35.88 kg/m2. The medianminimum JSWat inclusionwas 3.67 mm
(min: 0.57 mm- max: 7.21 mm). After 18 and 30 months, the minimum
JSW was 3.59 mm (min: 0 mm - max: 6.60 mm) and 3.54 mm (0 mm-6.49
mm), respectively. Linear regression analysis showed that 64% of subjects
experienced a decrease of JSW over 30 months. Among this population,
124 patients (68%) were radiographic nonprogressors while 58 patients
(32%) were radiographic progressors. At baseline, uColl2-1NO2 concen-
tration was 1.25 times higher (p<0.01) in radiographic progressor patients
(median: 0.0254 nmol/mmol Cr; min: 0.0073 - max: 0.1890 nmol/mmol
Cr) compared to the nonprogressor patients (0.0204 nmol/mmol Cr; min:
0.0043 - max: 0.0637 nmol/mmol Cr). By logistic regression in this pop-
ulation, patients with a high uColl2-1NO2 concentration at baseline (i.e.
0.172 nmol/mmol Cr) had a high probability (98%) of being radiographic
progressors (p<0.001). Also patients with an increase ( 0.0362 nmol/
mmol Cr) of uColl2-1NO2 over 16 months had a high probability (92%) of
being radiographic progressors.
Conclusions: The results of the both studies agree well and show
a consistent capability of urinary Coll2-1NO2 to predict knee OA progres-
sion. Speciﬁcally, the 16-month change in urinary Coll2-1NO2 is a useful
predictor of radiographic progression of knee OA over 30 months in two
independent populations totaling a sample size of 317 patients.
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CHANGES IN SYNOVIAL FLUID LEVELS OF ARGS-AGGRECAN ARE
ASSOCIATED WITH PROGRESSION OF RADIOGRAPHIC
OSTEOARTHRITIS AND PAIN IN SUBJECTS WITH PREVIOUS
MENISCECTOMY
S. Larsson 1, M. Englund 1,2, A. Struglics 1, S. Lohmander 1,3. 1Dept. of
Orthopaedics, Clinical Sci. Lund, Lund Univ., Lund, SWEDEN; 2Clinical
Epidemiology Res. & Training Unit, Boston Univ. Sch. of Med., Boston, MA;
3Res. Unit for Musculoskeletal Function and Physiotherapy, and Dept. of
Orthopaedics and Traumatology, Univ. of Southern Denmark, Odense,
DENMARK
Purpose: To investigate whether change in concentrations over time of
aggrecanase generated ARGS-aggrecan in synovial ﬂuid (SF ARGS) associ-
ates with progression of radiographic knee osteoarthritis (OA) and patient-
reported outcome in subjects with previous meniscectomy.
Methods: We studied 74 subjects whom at ﬁrst examination were mean
(range) 52 (32 to 73) years old and had beenmeniscectomized 18 (15 to 22)
years earlier, with a follow up examination 7.5 (4 to 10) years later. We
obtained synovial ﬂuid, patient-reported outcomes, standing tibiofemoral
and skyline patellofemoral radiographs at both examinations. We
measured SF ARGS by an electrochemiluminescence immunoassay using
an anti-aggrecan antibody (AHP0022; Invitrogen) for capture, and
amonoclonal anti-ARGS (OA-1) for detection. Radiographic outcomes (loss
of joint space, osteophyte progression, and radiographic OA progression)
were based on progression from ﬁrst to second examination of the scores
of joint space narrowing (JSN), osteophytes, and either JSN or osteophytes
or both, scored according to the OARSI atlas; progressionwas deﬁned as an
increase in the respective scores with one or more. Patient-reported
outcomes was assessed by Knee injury and Osteoarthritis Outcome Score
(KOOS) with the ﬁve dimensions, pain, other symptoms, function of daily
living, function in sports and recreation, and knee-related quality of life;
progression was deﬁned as a worsening in the respective score by 10 units
or more. To study the association between the change in levels of SF ARGSbetween examinations and progression of radiographic OA and KOOS, we
created a dichotomous SF ARGS variable (increase or decrease) and used
multivariate logistic regression adjusted for age, gender, body mass index,
time between examinations, and SF ARGS at ﬁrst examination.
Results: SF ARGS levels were mean (and range) 6.66 (0.15-14.58) and 7.06
(0.12-14.71) pmol ARGS/ml at ﬁrst and second examinations respectively,
and showed a correlation between examinations (Pearson's correlation
coefﬁcient ¼ 0.611, P< 0.001). There was a signiﬁcant association between
decreasing levels of SF ARGS and loss of joint space and worsening of KOOS
pain: in subjects with decreasing SF ARGS between examinations, the
likelihood of loss of joint space and worsening of KOOS pain between
examinations was increased 6- and 4-fold, respectively, compared to those
increasing in SF ARGS (Table 1). No signiﬁcant associations were seen
between decreasing SF ARGS and osteophyte progression, or patient-
reported outcomes other than KOOS pain.
Conclusions: In middle-aged subjects with a meniscectomy 18 years
earlier, decreasing levels of SF ARGS over the next four to ten years were
associated with an increased risk for loss of joint space and worsening of
knee pain over the same time period, but showed no association with
other patient-reported outcomes or osteophyte progression.
Ă
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CAN THE DIAGNOSTIC AND PROGNOSTIC CAPACITY OF OA BIOMARKERS
BE IMPROVED BY COMBINING MULTIPLE FACTORS?
N. Fukui 1,2, N. Tanaka 2, Y. Ikeda 2, M. Wake 2, T. Yamaguchi 2,
S. Yamane 3. 1Graduate Sch. of Arts and Sci., the Univ. of Tokyo, Tokyo, JAPAN;
2Clinical Res. Ctr., Natl. Hosp. Organization Sagamihara Hosp., Sagamihara,
Kanagawa, JAPAN; 3 Shionogi Pharmaceutical Co., Osaka, JAPAN
Purpose:: Although many biomarkers are known to have diagnostic and
prognostic capacity for knee OA, few of them are reliable enough to be used
clinically. Some investigators have attempted to improve the diagnostic
performance of biomarkers by measuring two ormore biomarkers together,
but it has not been known if this strategy is indeed useful or not. In this
study, we attempted to know the best possible combinations of biomarkers
for knee OA for the diagnosis and the prediction of disease progression.
Methods: The study included 43 knee OA patients (mean, 71.7 years), and
30 age matched healthy volunteers (mean, 68.5 years). To be included in the
study, an OA patient had to be at least 50 years old, and have medially
involved knee OA in at least one of the knee joints. The diagnosis of knee OA
was based on the ACR criteria, and the knees with the severest stage of OA
(Kellgren-Lawrence grade 4) were excluded from the study because
progression of joint space narrowing was not evaluated with such knees. All
knee OA patients were followed up for 2 years, during which the patients
were asked to visit clinics every 6 months. For these patients, knee radio-
graphs were taken in the weight-bearing ﬁxed-ﬂexion method (Peterfy,
2003), and blood and urine samples were obtained at each visit. Progression
of knee OAwas determined on the radiographs, bymeasuring the narrowest
width between the femur and tibia in the medial compartment. Since
radiographs were obtained every 6 months, we were able to specify the 6-
month periods in which the narrowing actually occurred. Blood and urine
samples were obtained once from the healthy controls.
Fourteen serum biomarkers and 6 urine biomarkers, which have been
reported to associate with the pathology of knee OA, were measured with
serumandurine samples, respectively (Table). Themarkerswere compared
